Patents by Inventor Samuel Hou
Samuel Hou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11891454Abstract: The present invention describes hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: GrantFiled: July 17, 2020Date of Patent: February 6, 2024Assignee: Ichnos Sciences SAInventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
-
Patent number: 11851502Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: GrantFiled: May 21, 2018Date of Patent: December 26, 2023Assignee: Ichnos Sciences SAInventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
-
Patent number: 11773166Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.Type: GrantFiled: October 12, 2018Date of Patent: October 3, 2023Assignee: Ichnos Sciences SAInventors: Romain Ollier, Samuel Hou, Rami Lissilaa, Darko Skegro, Jonathan Back
-
Publication number: 20230062624Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.Type: ApplicationFiled: June 9, 2022Publication date: March 2, 2023Inventors: Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO, Jonathan BACK
-
Publication number: 20220411526Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: June 30, 2022Publication date: December 29, 2022Inventors: Antoine ATTINGER, Stanislas BLEIN, Jonathan Albert BACK, Rami LISSILAA, Samuel HOU
-
Patent number: 11407839Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: GrantFiled: March 11, 2019Date of Patent: August 9, 2022Assignee: Ichnos Sciences SAInventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
-
Patent number: 11267891Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2 integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.Type: GrantFiled: January 28, 2015Date of Patent: March 8, 2022Assignee: SANOFIInventors: Stanislas Blein, Samuel Hou, Darko Skegro
-
Publication number: 20210171661Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: ApplicationFiled: July 17, 2020Publication date: June 10, 2021Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Samuel HOU
-
Patent number: 10640564Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.Type: GrantFiled: October 19, 2015Date of Patent: May 5, 2020Assignee: Ichnos Sciences SAInventors: Rami Lissilaa, Adrian Walmsley, Stanislas Blein, Romain Ollier, Samuel Hou, Jeremy Loyau
-
Publication number: 20200071409Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: March 11, 2019Publication date: March 5, 2020Inventors: Antoine ATTINGER, Stanislas BLEIN, Jonathan Albert BACK, Rami LISSILAA, Samuel HOU
-
Publication number: 20190135918Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.Type: ApplicationFiled: October 12, 2018Publication date: May 9, 2019Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO, Jonathan BACK
-
Publication number: 20180355064Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: ApplicationFiled: May 21, 2018Publication date: December 13, 2018Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Samuel HOU
-
Publication number: 20180086836Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.Type: ApplicationFiled: October 19, 2015Publication date: March 29, 2018Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Rami LISSILAA, Adrian WALMSLEY, Stanislas BLEIN, Romain OLLIER, Samuel HOU, Jeremy LOYAU
-
Publication number: 20170260280Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: November 10, 2016Publication date: September 14, 2017Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
-
Publication number: 20170145115Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: ApplicationFiled: June 23, 2016Publication date: May 25, 2017Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou
-
Patent number: 9493563Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: GrantFiled: November 4, 2014Date of Patent: November 15, 2016Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
-
Publication number: 20150232559Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2 integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.Type: ApplicationFiled: January 28, 2015Publication date: August 20, 2015Inventors: Stanislas Blein, Samuel Hou, Darko Skegro
-
Publication number: 20150133640Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: ApplicationFiled: November 4, 2014Publication date: May 14, 2015Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou
-
Patent number: 8975376Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.Type: GrantFiled: February 22, 2011Date of Patent: March 10, 2015Assignee: SanofiInventors: Stanislas Blein, Samuel Hou, Darko Skegro
-
Publication number: 20140294824Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: March 21, 2014Publication date: October 2, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou